Lanz Caroline, Schotsaert Michael, Magnus Carsten, Karakus Umut, Hunziker Annika, Sempere Borau Milagros, Martínez-Romero Carles, Spieler Eva E., Günther Sira C., Moritz Eva, Hale Benjamin G., Trkola Alexandra, García-Sastre Adolfo, Stertz Silke (2021), IFITM3 incorporation sensitizes influenza A virus to antibody-mediated neutralization, in Journal of Experimental Medicine
, 218(6), e20200303.
Sempere Borau Milagros, Stertz Silke (2021), Entry of influenza A virus into host cells — recent progress and remaining challenges, in Current Opinion in Virology
, 48, 23-29.
Pohl Marie O., Busnadiego Idoia, Kufner Verena, Glas Irina, Karakus Umut, Schmutz Stefan, Zaheri Maryam, Abela Irene, Trkola Alexandra, Huber Michael, Stertz Silke, Hale Benjamin G. (2021), SARS-CoV-2 variants reveal features critical for replication in primary human cells, in PLOS Biology
, 19(3), e3001006-e3001006.
Stertz Silke, Hale Benjamin G. (2021), Interferon system deficiencies exacerbating severe pandemic virus infections, in Trends in Microbiology
Günther Sira Carolin, Maier Julian David, Vetter Janine, Podvalnyy Nikita, Khanzhin Nikolay, Hennet Thierry, Stertz Silke (2020), Antiviral potential of 3′-sialyllactose- and 6′-sialyllactose-conjugated dendritic polymers against human and avian influenza viruses, in Scientific Reports
, 10(1), 768-768.
Spieler Eva E., Moritz Eva, Stertz Silke, Hale Benjamin G. (2020), Application of a Biologically Contained Reporter System To Study Gain-of-Function H5N1 Influenza A Viruses with Pandemic Potential, in mSphere
, 5(4), e00423-20.
Influenza viruses pose a huge burden on human health but also cause substantial economic losses due to illness-related absences from work and costs for managing influenza outbreaks in animals, such as pigs or chicken. Currently, vaccines and antiviral drugs are available, but unfortunately both come with severe limitations and novel concepts for vaccines and antivirals are needed. With our research we contribute to the development of antiviral drugs for influenza. Our approach aims to identify host cell factors required for influenza virus entry into its host cell and characterize their proviral mechanism of action. Such host factors could be exploited as drug targets if their function is essential for virus infection but not required for cell viability. Of particular interest are entry factors with a proviral catalytic function, such as proteases or kinases, as these are amenable to small molecular weight compound screening in in vitro assays.In our previous work we identified and characterized a number of entry factors for influenza virus using RNAi screening approaches but also a newly developed phospho-proteomic protocol to study host cell signaling events induced early in infection. Here, we aim to establish one of the identified entry factors, Cathepsin W, as a drug target for influenza and extend our efforts to reveal drug target candidates to other respiratory viruses.